Search results for "LEASING"

showing 10 items of 140 documents

Study of pituitary secretion in relation to retinopathy in patients with juvenile diabetes mellitus.

1981

Fifteen juvenile diabetic patients with normal eye fundus, 6 with non proliferative retinopathy, 5 with proliferative retinopathy and 5 healthy control subjects were studied in order to investigate pituitary function in relation to diabetic retinopathy. ACTH values at 08(00) and 18(00), hPRL and TSh secretion in response to 200 microgram TRH i.v., and GH secretion in response to 500 mg oral L-dopa were evaluated. In all diabetic subjects, 08(00) ACTH levels were lower than in controls. Basal hPRL, TSH and GH values of the diabetics did not differ from those of the controls. No significant differences were found in hPRL levels in response to TRH, whereas significantly lower TSH responses wer…

AdultMaleendocrine systemPituitary glandmedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismThyrotropin-releasing hormoneThyrotropinAdrenocorticotropic hormoneLevodopaEndocrinologyAdrenocorticotropic HormoneInternal medicineDiabetes mellitusInternal MedicineMedicineHumansThyrotropin-Releasing HormoneDiabetic Retinopathybusiness.industryGeneral MedicineDiabetic retinopathymedicine.diseaseGrowth hormone secretionProlactinProlactinKineticsmedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 1Growth HormonePituitary GlandFemalebusinesshormones hormone substitutes and hormone antagonistsRetinopathyActa diabetologica latina
researchProduct

Thyrotropin-releasing hormone has stimulatory effects on ventilation in humans

1991

Thyrotropin-releasing hormone (TRH) stimulates pituitary thyrotropin synthesis and release and also regulates autonomic nervous system functions by acting as a neuromodulator and neurotransmitter. In experimental animals a stimulation of ventilation by thyrotropin-releasing hormone was shown when applied at central nervous system sites that affect respiratory motor output. It was the goal of our study to investigate the respiratory properties of thyrotropin-releasing hormone on basal and stimulated (i.e. CO2-rebreathing) conditions following systemic thyrotropin-releasing hormone application in healthy humans. Thyrotropin-releasing hormone (200 micrograms, 400 micrograms intravenous) initia…

AdultMaleendocrine systemmedicine.medical_specialtyAdolescentRespiratory ratePhysiologyStatistics as TopicCentral nervous systemThyrotropin-releasing hormoneInternal medicinemedicineHumansRespiratory systemThyrotropin-Releasing Hormonebusiness.industryRespirationRespiratory Function TestsAutonomic nervous systemmedicine.anatomical_structureEndocrinologyBreathingFemalebusinessRespiratory minute volumeHormoneActa Physiologica Scandinavica
researchProduct

Effects of corticotropin-releasing hormone on respiratory parameters during sleep in normal men.

2009

Corticotropin-releasing hormone (CRH) is well-known to be a centrally acting respiratory stimulant after systemic application both in healthy subjects and in patients suffering from respiratory failure. In order to study the effects of CRH on sleep EEG and respiratory parameters during sleep, 14 healthy male volunteers were investigated in a single-blind placebo controlled design. After an adaptation night, polysomnography was performed during two successive nights between 23.00 hrs. and 7.00 hrs. During one night placebo was applied, on the other 50 μg ovine CRH was administered intravenously as a bolus every hour from 0.00 hrs. to 6.00 hrs. For the assessment of respiration, blood oxygen …

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneCorticotropin-Releasing HormoneEndocrinology Diabetes and MetabolismSleep REMPolysomnographyPlacebosCorticotropin-releasing hormoneEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodSleep and breathingInternal medicineInternal MedicinemedicineHumansRespiratory systemTidal volumeSlow-wave sleepmedicine.diagnostic_testbusiness.industryElectromyographyRespirationElectroencephalographyGeneral MedicineThoraxOxygenKineticsEndocrinologyRespiratory failureAnalepticAnesthesiabusinessSleephormones hormone substitutes and hormone antagonistsExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Naloxone increases the response of growth hormone and prolactin to stimuli in obese humans.

1987

Opiates stimulate the growth hormone and prolactin responses to stimuli in non-obese humans. Obese patients, however, show lowered growth hormone and prolactin responses and raised beta-endorphin levels. We therefore investigated the effect of the opiate antagonist naloxone on the stimulated growth hormone and prolactin secretions in a controlled double-blind study in obese patients. All patients received 200 micrograms TRH and 0.5 g/kg b.w. arginine together with 2 mg of naloxone or placebo i.v. in a randomized sequence. The TRH- and arginine-induced increases in prolactin and growth hormone were significantly greater after administration of naloxone (p less than 0.05). Naloxone also produ…

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and Metabolismmedicine.medical_treatment(+)-NaloxoneArginineGlucagonEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodInternal medicinemedicineHumansObesityOpioid peptideThyrotropin-Releasing HormoneTriiodothyroninebusiness.industryNaloxoneInsulinbeta-EndorphinAntagonistMiddle AgedProlactinProlactinEndocrinologyGrowth HormoneFemaleEndorphinsOpiatebusinesshormones hormone substitutes and hormone antagonistsJournal of endocrinological investigation
researchProduct

The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients

1995

Roxindole is a potent autoreceptor-selective dopamine agonist with additional properties as a serotonin reuptake inhibitor and 5-HT1A agonist. In order to get more insight into its mode of action in various psychiatric populations, we evaluated the effects of subchronic roxindole treatment on pituitary and adrenal hormone secretion, i.e. release of prolactin, thyroid stimulating hormone (TSH), growth hormone (GH), luteinizing hormone (LH), and cortisol. Fifteen schizophrenic patients with positive and negative symptomatology, respectively, were treated with roxindole for 28 days. Both basal and thyrotropin releasing hormone (TRH) -induced prolactin secretion diminished significantly to 26.4…

AdultMaleendocrine systemmedicine.medical_specialtyIndolesHydrocortisoneendocrine system diseasesPyridinesThyrotropinThyrotropin-releasing hormonePharmacologyDopamine agonistchemistry.chemical_compoundThyroid-stimulating hormoneAnterior pituitaryRoxindoleInternal medicinemedicineHumansPharmacologybusiness.industryLuteinizing HormoneMiddle AgedProlactinGrowth hormone secretionOxindolesProlactinEndocrinologymedicine.anatomical_structurechemistryGrowth HormoneDopamine AgonistsSchizophreniaFemaleSchizophrenic PsychologyLuteinizing hormonebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugPsychopharmacology
researchProduct

Time-related effects of thyrotropin-releasing hormone (TRH) on the pituitary-thyroid axis and extrathyroidal targets.

2009

Thyrotropin-releasing hormone (TRH) is a tripeptide and acts as a stimulator of the pituitary-thyroid axis as well as having a great number of well defined extrathyroidal functions. Studies in experimental animals have shown, that TRH also has a role as a neuromodulator within the autonomous nervous system. In this study we analyzed the effects following peripheral administration of TRH (200 micrograms, 400 micrograms) in patients with endocrinological disorders and in healthy females and males. By means of a questionnaire, patients were asked about possible (side-) effects; ventilatory and cardiovascular monitoring was performed during steady state. The pulsatile TSH-secretion pattern was …

AdultMaleendocrine systemmedicine.medical_specialtyTime Factorsendocrine system diseasesEndocrinology Diabetes and MetabolismThyrotropin-releasing hormoneThyrotropinStimulationEndocrine System DiseasesNorepinephrine (medication)Pituitary thyroid axisEndocrinologyHeart RateInternal medicineSurveys and QuestionnairesHeart rateInternal MedicinemedicineHumansThyrotropin-Releasing Hormonebusiness.industryRespirationThyroidGeneral Medicinemedicine.anatomical_structureEpinephrineEndocrinologyFemalebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugHormoneExperimental and clinical endocrinology
researchProduct

Gonadotropin and Testosterone Secretion in Normal Human Males After Stimulation With Gonadotropin-Releasing Hormone (Gnrh) or Potent Gnrh Analogs Usi…

1978

Gonadotropin-releasing hormone (GnRH) and some potent long-acting GnRH analogs, applied by different routes of administration, were tested in six healthy human males. The effects on gonadotropin secretion were compared with the one after intravenous (i.v.) bolus injection of 25 microgram of GnRH. The net increase of luteinizing hormone (deltaLH) in serum produced by 25 microgram of GnRH i.v. was matched by subcutaneous (s.c.) injection of 100 microgram of GnRH, dissolved in 20% gelatin or without gelatin; 5 microgram of D-Ser (TBU)6-des-Gly10-GnRH-ethylamide i.v.; 5 microgram of D-Leu6-des-Gly10-GnRH-ethylamide i.v.; and 50 microgram of D-Trp6-des Gly10-GnRH-ethylamide given pernasally (p.n…

AdultMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classMicrogramStimulationGonadotropin-releasing hormoneGonadotropin-Releasing HormoneInternal medicinemedicineHumansInfusions ParenteralTestosteroneAdministration IntranasalChemistryObstetrics and GynecologyLuteinizing HormoneHormonesGonadotropin secretionEndocrinologyReproductive MedicineInjections IntravenousNasal administrationFollicle Stimulating HormoneGonadotropinLuteinizing hormonePituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Neuroendocrine response to antipsychotics: effects of drug type and gender

1999

Abstract Background: To study the influences of drug type and gender on the neuroendocrine response to neuroleptic treatment, we compared the endocrine actions of two neuroleptics with different receptor affinity profiles—a substituted benzamide, amisulpride, a selective D 2 -like dopamine antagonist; and a thioxanthene, flupenthixol, a mixed D 1 /D 2 -like antagonist also blocking serotonin, H 1 , and D 1 receptors—on anterior pituitary hormone secretion in schizophrenic patients (DSM-III-R). Methods: Blood was withdrawn at 15-min intervals to assess basal secretion of prolactin, growth hormone (GH), and thyroid-stimulating hormone (TSH). Four hundred micrograms of thyrotropin-releasing ho…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesThyrotropinThyrotropin-releasing hormoneFlupenthixolPharmacologySex FactorsDouble-Blind MethodAnterior pituitaryThyroid-stimulating hormoneInternal medicinemedicineHumansAmisulprideBiological PsychiatryHuman Growth Hormonebusiness.industryDopamine antagonistNeurosecretory SystemsProlactinProlactinFlupenthixolmedicine.anatomical_structureEndocrinologySchizophreniaFemaleSchizophrenic PsychologyAmisulprideSulpiridebusinesshormones hormone substitutes and hormone antagonistsAntipsychotic Agentsmedicine.drugHormoneBiological Psychiatry
researchProduct

Stimulation of Spermatogenesis and Biological Paternity by Intranasal (Low Dose) Gonadotropin-Releasing Hormone (GnRH) in a Male with Kallmann's Synd…

1987

Intranasal (in) GnRH spray caused induction and maintenance of spermatogenesis and biological paternity in a 28-yr-old man with Kallmann's syndrome. Prior treatment had included GnRH analog administration, which failed to induce puberty, and testosterone (T) enanthate weekly. Prior hCG/human menopausal gonadotropin therapy had resulted in high normal serum T levels and near-normal semen quality, but during subsequent hCG therapy, spermatogenesis markedly decreased. The patient had then received 250 mg T enanthate/month for 2 yr and 7 months; it was discontinued 7 weeks before the in GnRH study began. At its start (July 1984) the subject's testis size was 7 mL, and he had azoospermia, low se…

AdultMaleendocrine systemmedicine.medical_specialtymedicine.drug_classKallmann syndromeEndocrinology Diabetes and MetabolismClinical BiochemistryPaternityGonadotropin-releasing hormoneBiologyBiochemistryOlfaction DisordersEndocrinologyInternal medicinemedicineHumansSpermatogenesisTestosteroneAzoospermiaHypogonadismBiochemistry (medical)Syndromemedicine.diseaseSpermStimulation ChemicalEndocrinologyGonadotropinMenotropinsPituitary Hormone-Releasing HormonesSpermatogenesisGonadotropinshormones hormone substitutes and hormone antagonistsThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Testicular Sperm Extraction (TESE) and Intracytoplasmic Sperm Injection (ICSI) in Hypogonadotropic Hypogonadism with Persistent Azoospermia After Hor…

2004

Purpose: We aimed to retrieve testicular sperm to be employed on intracytoplasmic sperm injection (ICSI) cycles on a male affected of hypogonadotropic hypogonadism (HH) that remained azoospermic after long-time hormonal treatment. Methods: Design. We initially performed hormonal therapy using gonadotropins to achieve spermatogenesis. After several semen analyses, we weighed the possibility of looking for testicular spermatozoa for ICSI. Setting. A private university-affiliated setting. Patient. A 30-years-old man diagnosed 10 years ago to suffer from idiopathic, prepubertal HH. Interventions. Gonadotrophin treatment was initiated with hCG and follicle stimulating hormone (FSH). Testicular s…

AdultMaleendocrine systemmedicine.medical_treatmentSemenArticleIntracytoplasmic sperm injectionGonadotropin-Releasing HormoneAndrologyFollicle-stimulating hormonePregnancyHypogonadotropic hypogonadismGeneticsmedicineHumansTestosteroneSperm Injections IntracytoplasmicSpermatogenesisreproductive and urinary physiologyGenetics (clinical)CryopreservationAzoospermiaurogenital systembusiness.industryHypogonadismPregnancy OutcomeObstetrics and GynecologyOligospermiaGeneral MedicineLuteinizing Hormonemedicine.diseaseSpermatozoaSpermTesticular sperm extractionReproductive MedicineFemaleFollicle Stimulating HormoneLuteinizing hormonebusinesshormones hormone substitutes and hormone antagonistsSemen PreservationDevelopmental BiologyJournal of Assisted Reproduction and Genetics
researchProduct